印度易瑞沙各种疑问解答doc（India Iressa various questions of doc）.doc

印度易瑞沙各种疑问解答doc（India Iressa various questions of doc） Q: what are the 1 lung cancer patients for treatment with Iressa? Answer: Iressa for the treatment of previously treated or not suitable for radiotherapy and chemotherapy for locally advanced or metastatic non-small cell lung cancer. Question 2: under what conditions is easy for lung cancer treatment effect of Iressa? Answer: at present the clinical research results show that Iressa race for the East (Asians), female, non smoker, high efficacy of alveolar cell carcinoma or adenocarcinoma patients. But the main factor is not (Oriental (Asians), women, non-smokers), but the type of lung cancer and physical characteristics of the patient himself. Question 3: adenocarcinoma of the efficacy of Iressa is high, then the risk of squamous cell carcinoma or other non-small cell lung cancer patients taking Iressa effective? Answer: easy effect Relenza of lung squamous cell carcinoma than adenocarcinoma and bronchioloalveolar carcinoma is low. But the selection of Iressa in the treatment of patients according to the actual situation, there are still some lung squamous cell carcinoma and other non-small cell lung cancer patients taking Iressa could be observed after the obvious curative effect. 4: asked at the end of last year in the United States of an international multi center clinical trial of Iressa (ISEL) preliminary analysis showed that Iressa can prolong the survival time of patients with lung cancer, but why Iressa still officially listed in China? Answer: according to the information provided by AstraZeneca, the clinical trial results showed that it was not possible to extend the overall life of the patient, but the experiment also found that Iressa to participate in the test of Oriental survival time more than 8 months or longer, the longest survival of patients have been 5 years for a long time, and the body is still very good. The overall survival and remission rates in the Eastern population were significantly b